8-K: CG Oncology's Cretostimogene Shows Promising Durability and Safety in Bladder Cancer Trial

CG Oncology announces positive Phase 3 trial results for cretostimogene in BCG-unresponsive non-muscle invasive bladder cancer, demonstrating a 75.5% complete response rate and a median duration of response exceeding 28 months.

Summary

• CG Oncology reported updated data from its BOND-003 Phase 3 clinical trial for cretostimogene in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
• The data showed that 75.5% of patients (83 out of 110) achieved a complete response (CR) at any time.
• As of the data cutoff date of January 20, 2025, the median duration of response (DOR) had not been reached but exceeded 28 months.
• Cretostimogene was generally well-tolerated, with no Grade 3 or greater treatment-related adverse events (TRAEs) or deaths reported.
• 97.3% of patients completed all expected treatments, indicating favorable patient adherence.
• The most common TRAEs (10%) were bladder spasm, pollakiuria, micturition urgency, dysuria, and hematuria.
• Translational data indicates that post-treatment close contact precautions are unnecessary.

Sentiment

Score: 8

Explanation: The document presents highly positive clinical trial results with strong efficacy and safety data, suggesting a favorable outlook for the company and its lead product candidate.

Positives

• High complete response rate of 75.5% in the BOND-003 trial.
• Durable response, with the median duration exceeding 28 months.
• Favorable safety profile with no Grade 3 or greater treatment-related adverse events or deaths reported.
• High patient adherence, with 97.3% completing all expected treatments.
• Translational data suggests no need for close contact precautions post-treatment.

Risks

• Additional patient data may be inconsistent with the data produced as of the data cutoff.
• Further analysis of existing data and analysis of new data may lead to conclusions different from those established as of the date hereof.
• Unexpected adverse side effects or inadequate efficacy of cretostimogene may limit its development, regulatory approval, and/or commercialization.
• Potential delays in the commencement, enrollment and completion of clinical trials.
• Competitive developments with respect to current and other investigational NMIBC treatments may adversely affect the commercial opportunity of cretostimogene.

Future Outlook

The company anticipates that cretostimogene has the potential to be a best-in-class durable response and meaningfully improve patient outcomes for high-risk and intermediate-risk NMIBC patients.

Management Comments

• Trinity J. Bivalacqua, M.D., stated that cretostimogene's strong safety and efficacy profile, combined with its best-in-class durability, address an unmet need for non-muscle invasive bladder cancer patients and that he is confident that cretostimogene will represent a breakthrough in bladder cancer treatment, if approved by the FDA.
• Ambaw Bellete, President & Chief Operating Officer, CG Oncology, stated that they are highly encouraged by the latest BOND-003 results and cretostimogene's potential to significantly impact the future of bladder cancer care.

Industry Context

The announcement highlights CG Oncology's progress in the competitive bladder cancer treatment landscape, particularly in the area of BCG-unresponsive NMIBC, where there is a significant unmet need for bladder-sparing therapies.

Comparison to Industry Standards

• The 75.5% complete response rate observed in the BOND-003 trial appears competitive when compared to other therapies in the BCG-unresponsive NMIBC space, such as Keytruda (pembrolizumab) which has shown lower complete response rates.
• The median duration of response exceeding 28 months is also a positive indicator, suggesting a potentially more durable treatment option compared to some existing therapies.
• However, direct comparisons are challenging without considering differences in trial design, patient populations, and specific endpoints.

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results.
• Patients with BCG-unresponsive NMIBC may benefit from a new bladder-sparing treatment option.
• Healthcare providers may have a new tool to manage this challenging patient population.

Next Steps

• CG Oncology will continue to evaluate cretostimogene in ongoing clinical trials, including PIVOT-006 and investigator-sponsored trials.
• The company will likely pursue regulatory approval from the FDA based on the BOND-003 data.

Key Dates

Keywords

cretostimogene, bladder cancer, NMIBC, CG Oncology, BOND-003, clinical trial, complete response, immunotherapy